ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1702

Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss

Yunwei Xia1, Naomi I. Maria2, Zhengzi Yi3, Chirag Raparia4, Gayathri Konanur Gopikrishna1, Weijia Zhang3 and Anne Davidson2, 1Feinstein Institutes for Medical Research, Manhasset, 2Feinstein Institutes for Medical Research, Manhasset, NY, 3Mt. Sinai School of Medicine, New York, NY, 4Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Shoreham, NY

Meeting: ACR Convergence 2024

Keywords: antiphospholipid syndrome, macrophages, Natural Killer Cells, pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Innate Immunity: Molecular Insights Into Immune Dysregulation

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Antiphospholipid antibodies (aPL) confer a high risk for adverse pregnancy outcomes, especially in women with SLE. aPLs can induce pro-inflammatory signaling via TLR8 receptors, but mouse models to study the role of TLR8 are limited due to the attenuated ssRNA-binding capacity of mouse TLR8. We generated a spontaneous model of aPL-induced pregnancy loss by crossing Sle1 mice with mice expressing a human TLR8 transgene (Sle1.huTLR8tg). Sle1.huTLR8tg mice but not Sle1 or C57BL6.huTLR8tg mice have a high frequency of pregnancy loss, demonstrating the requirement for both autoantibodies and TLR8 in fetal-placental injury.

Methods: Bulk RNA-sequencing was conducted on feto-placental units from Sle1 and Sle1.huTLR8tg  mice at Day E8.5 (day of peak decidualization and spiral artery remodeling) and Day E13.5 (at which time the placenta has been fully formed). qPCR was performed to validate RNAseq findings. Uterine natural killer (uNK) cells were identified at Day E9.5 on flow cytometry as Lin- NK1.1+ cells, and further classified into tissue-resident (CD49a+) or circulating (CD49b+) subsets. DBA lectin was used to identify uNK cells on IHC. Placental myeloid cell subsets were analyzed in the same tissues by flow cytometry. Sle1.huTLR8tg to Sle1 bone marrow chimeras were generated and placentas from pregnant chimeras were analyzed for myeloid subsets by flow cytometry.

Results: Placental abnormalities in Sle1.huTLR8tg mice include attenuation of vessels in the labyrinth, thinning of the junctional zone, thickened arterial walls, placental infarcts and inflammation. Bulk RNA sequencing of Sle1.huTLR8tg placentas at Days E8.5 and E13.5 showed a suppressed uNK cell gene signature, confirmed by qPCR (Fig. 1b). Flow cytometry (Fig. 2a) and IHC (Fig. 2b) demonstrated a decrease in uNK cell number in Day E9.5 Sle1.huTLR8tg feto-placental units with no difference in the frequency of tissue-resident vs. circulating uNK subsets. Concurrently, an upregulation of myeloid-related genes was observed at Day E8.5 (Fig 1c). A continued decrease in placental NK cells and thinning of the junctional zone were evident at Day E13.5. Analysis of placentas from bone marrow chimeras indicated preferential recruitment of huTLR8tg myeloid cells to the placentas.

Conclusion: Sle1.huTLR8tg mice are the first spontaneous model for aPL-induced pregnancy loss and demonstrate early placental developmental defects including a loss of uNK cells and junctional zone trophoblasts, the major cell types involved in placental spiral artery remodeling. An increase in placental myeloid cells in Sle1.huTLR8tg placentas may indicate an upstream regulatory defect affecting uNK cell proliferation and/or recruitment. Similar immune defects have recently been described in 1st trimester human APS placentas. Subsequent  compromise of the placental vasculature leads to the classical features of placental infarction and inflammation. Our findings suggest a possible role for human TLR8 in aPL-induced pregnancy loss with potential therapeutic implications. Further studies are needed to understand the factors regulating uNK cell function and recruitment to the placenta, including a potential role for myeloid cells.

Supporting image 1

Fig 1. A. Volcano plot showing downregulated genes (p=0.05), with NK-related genes in red. B. RT-qPCR of NK-related genes in d8.5 placentas. C. Top 30 downregulated genes in d8.5 Sle1.huTLR8tg placentas.

Supporting image 2

Fig 2. A. Representative NK1.1+ histograms from B57BL/6, Sle1, and Sle1.huTLR8.tg d9.5 placentas (left). Quantification of NK1.1+ cells as a percentage of total placental cells, and CD49a+ and CD49b+ subsets as a percentage of NK1.1+ cells (right). B. DBA lectin with PAS counterstaining IHC (top) and DBA lectin IF (bottom) in d9.5 Sle1 placentas (left) and Sle1.huTLR8.tg placentas (right).


Disclosures: Y. Xia: None; N. Maria: None; Z. Yi: None; C. Raparia: None; G. Konanur Gopikrishna: None; W. Zhang: None; A. Davidson: EMD Serono, 5.

To cite this abstract in AMA style:

Xia Y, Maria N, Yi Z, Raparia C, Konanur Gopikrishna G, Zhang W, Davidson A. Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/placental-developmental-defects-in-a-humanized-tlr8-mouse-model-of-spontaneous-anti-phospholipid-antibody-induced-pregnancy-loss/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/placental-developmental-defects-in-a-humanized-tlr8-mouse-model-of-spontaneous-anti-phospholipid-antibody-induced-pregnancy-loss/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology